In a Large Cap Pharma, Biopharma, & Biotech note, Cantor Fitzgerald analyst Louise Chen reiterated Overweight ratings on two anti-fungal stocks, Cidara Therapeutics (CDTX) and Scynexis (SCYX), with target prices of $5 and $15, respectively. The research note follows the CDC issuing a press release that highlighted "the increasing threat of the spread of antimicrobial-resistant fungus in healthcare facilities." which Cantor sees as "concerning," and emphasized the need for a "new effective treatment." The analyst believes both companies have potential positive catalysts in this space within the next 12-18 months, highlighting Cidara’s rezafungin and Scynexis’ Ibrexafungerp.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on CDTX:
- Cidara Therapeutics and Melinta Therapeutics Announce FDA Approval of REZZAYO™ (rezafungin for injection) for the Treatment of Candidemia and Invasive Candidiasis
- Cidara Therapeutics options imply 29.3% move in share price post-earnings
- Cidara Therapeutics options imply 14.0% move in share price post-earnings
- Cidara Therapeutics Presents Preclinical Data on CD73-Targeting Drug-Fc Conjugate at the 2023 ESMO Targeted Anticancer Therapies Congress
- Cidara Therapeutics Announces Closing of Public Offerings of Common Stock and Preferred Stock and Full Exercise of Underwriter’s Option to Purchase Additional Shares in Public Offering of Common Stock